TRLV · Mid Cap · Healthcare · Drug Manufacturers - Specialty & Generic
Free research brief
Free to track. No card required.
Price, momentum, and the numbers behind the story.
Overall score
53/100
See the full financial picture
Open the five-year record, valuation checks and Wall Street view behind these scores.
Free for 3 days, then $9/mo. Cancel anytime.
Where the analysts and the crowd stand, and what it's worth to know first.
Current price
$12.15
Lowest
$15
Median target
$19
Highest
$21
What it earns and where it earns it, what you're paying for the stock, and the risk sitting on the balance sheet.
Price / sales
Strong · Low price-to-sales
2.05x
Price / FCF
Strong · Cash flow supports price
11.51x
EV / EBITDA
Strong · Earnings support price
8.59x
Debt / equity
Favorable · 0.75 - solid leverage
0.75x
Current ratio
Strong · Good liquidity position
5.94x
Forward P/E
Needs attention · 45% above avg
27.21x
ROE
Needs attention · Unfavorable
-47.7%
TRLV against the names it's actually compared to.
| Company | Mkt cap | P/E | Rev growth | Score |
|---|---|---|---|---|
| $2.33B | - | -3.9% | 53 | |
| $10.51B | 20.0 | +19.7% | 78 | |
| $33.17B | 34.7 | +15.5% | 78 | |
| $4.12B | 12.4 | +13.5% | 78 | |
| $1.08T | 39.1 | +49.6% | 77 |